GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Cyclically Adjusted PB Ratio

Aceragen (Aceragen) Cyclically Adjusted PB Ratio : 0.01 (As of May. 21, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Aceragen Cyclically Adjusted PB Ratio?

As of today (2024-05-21), Aceragen's current share price is $0.38. Aceragen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2023 was $54.82. Aceragen's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for Aceragen's Cyclically Adjusted PB Ratio or its related term are showing as below:

ACGN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1.37   Max: 17.55
Current: 0.01

During the past years, Aceragen's highest Cyclically Adjusted PB Ratio was 17.55. The lowest was 0.01. And the median was 1.37.

ACGN's Cyclically Adjusted PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.725 vs ACGN: 0.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aceragen's adjusted book value per share data for the three months ended in Mar. 2023 was $2.701. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $54.82 for the trailing ten years ended in Mar. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aceragen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Aceragen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Cyclically Adjusted PB Ratio Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.43 1.11 0.18 0.09

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.15 0.14 0.09 0.04

Competitive Comparison of Aceragen's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Aceragen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aceragen's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aceragen's Cyclically Adjusted PB Ratio falls into.



Aceragen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aceragen's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.38/54.82
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aceragen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Aceragen's adjusted Book Value per Share data for the three months ended in Mar. 2023 was:

Adj_Book=Book Value per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=2.701/127.3478*127.3478
=2.701

Current CPI (Mar. 2023) = 127.3478.

Aceragen Quarterly Data

Book Value per Share CPI Adj_Book
201306 8.838 98.518 11.424
201309 56.665 98.790 73.045
201312 44.052 98.326 57.054
201403 101.216 99.695 129.291
201406 88.871 100.560 112.546
201409 74.961 100.428 95.055
201412 62.246 99.070 80.013
201503 130.693 99.621 167.068
201506 118.035 100.684 149.294
201509 106.485 100.392 135.077
201512 93.739 99.792 119.623
201603 81.486 100.470 103.285
201606 68.425 101.688 85.691
201609 55.865 101.861 69.843
201612 94.291 101.863 117.882
201703 82.248 102.862 101.827
201706 68.063 103.349 83.868
201709 56.406 104.136 68.979
201712 74.870 104.011 91.668
201803 62.233 105.290 75.271
201806 53.223 106.317 63.751
201809 46.827 106.507 55.990
201812 40.014 105.998 48.074
201903 33.791 107.251 40.123
201906 28.151 108.070 33.173
201909 22.165 108.329 26.056
201912 -6.398 108.420 -7.515
202003 -0.080 108.902 -0.094
202006 -8.770 108.767 -10.268
202009 -15.656 109.815 -18.156
202012 -40.478 109.897 -46.906
202103 15.454 111.754 17.610
202106 12.306 114.631 13.671
202109 10.633 115.734 11.700
202112 9.480 117.630 10.263
202203 8.301 121.301 8.715
202206 6.778 125.017 6.904
202209 5.982 125.227 6.083
202212 3.236 125.222 3.291
202303 2.701 127.348 2.701

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aceragen  (NAS:ACGN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aceragen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Aceragen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (Aceragen) Business Description

Industry
Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Executives
Vincent Milano director, officer: President & CEO C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen director
Pillar Invest Corp director, 10 percent owner C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra 10 percent owner C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor director, officer: Chief Executive Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan officer: Chief Strategy Officer C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain officer: Chief Operating Officer C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten director
Nq Pof V Gp, Ltd. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p. director, other: See Remarks 4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby officer: V.P. of Finance, PFO & PAO C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka officer: Chief Medical Officer 111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim officer: SVP & General Counsel C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341